Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

McKinsey
US Army
Queensland Health
Fuji
Fish and Richardson
Julphar
Merck
Healthtrust
Moodys
Chinese Patent Office

Generated: August 19, 2017

DrugPatentWatch Database Preview

Claims for Patent: ► Subscribe

« Back to Dashboard

Claims for Patent: ► Subscribe

Title: Method of treating leukemia or leukemoid diseases
Abstract:A method of leukemia or leukemoid disease treatment by administration of a vitamin D derivative with a hydroxyl group at 1.alpha.-position is disclosed. It is believed that the vitamin D derivative with a hydroxyl group at 1.alpha.-position is capable of treating cancer through redifferentiation of cancer cells and that this capability is inherent in vitamin D derivatives with a hydroxyl group at 1.alpha.-position.
Inventor(s): Suda; Tatsuo (Tachikawa, JP), Hirasawa; Yoshihei (Niigata, JP), Takahashi; Sachio (Niigata, JP), Abe; Etsuko (Tokyo, JP), Konno; Kunio (Tokyo, JP), Aoki; Tadao (Niigata, JP)
Assignee: Chugai Seiyaku Kabushiki Kaisha (Tokyo, JP)
Application Number:06/356,385
Patent Claims: 1. A method for the treatment of leukemia or leukemoid diseases, comprising administering to a patient having such a disease an effective amount of a vitamin D derivative with a hydroxyl group at the 1.alpha.-position.

2. A method according to claim 1 wherein said derivative is administered in a soft capsule.

3. A method according to claim 1 wherein said derivative is administered in a daily dose of 0.5 to 5 .mu.g.

4. A method according to claim 1 for the treatment of leukemia, wherein the patient has leukemia.

5. A method according to claim 4 wherein the leukemia is a myelogenous leukemia.

6. A method according to claim 1 wherein said derivative is 1.alpha.-hydroxyvitamin D.sub.3.

7. A method according to claim 1 wherein said derivative is 1.alpha.,25-dihydroxyvitamin D.sub.3.

8. A method in accordance with claim 1, wherein said derivative is 1.alpha.-hydroxyvitamin D.sub.3, 1.alpha.,25-dihydroxyvitamin D.sub.3 or a mixture thereof.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

Healthtrust
US Army
Novartis
Argus Health
Mallinckrodt
UBS
Federal Trade Commission
Teva
Chinese Patent Office
Julphar

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted Heap | Mobile and Web Analytics
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot